

Contact: **Michael Beeuwsaert**
 President & CEO
 Numira Biosciences Inc.
 Tel: (801) 320-0682
 mbeeuwsaert@numirabio.com

NUMIRA BIOSCIENCES RAISES \$2 MILLION IN VENTURE CAPITAL FUNDING

SALT LAKE CITY, Utah, May 15, 2009 -- Numira Biosciences, a specialty contract research organization and leader in high-resolution, 3D visualization services for the life sciences market, today announced it had closed a \$2 million round of venture capital funding, led by returning investor, vSpring Capital. Crocker Ventures also participated in the funding.

The additional capital will support the continued growth of Numira's core imaging service, Virtual Histology™, an imaging technology that combines high-resolution computed tomography (microCT) with proprietary stains and high-performance software to provide quantitative, interactive datasets, in both 2D and 3D. Numira has established a new standard in soft tissue imaging with a broad range of applications in such areas as osteoarthritis, atherosclerosis, heart defects, lung fibrosis, angiogenesis, and developmental defects.

For more information on Numira Biosciences, please visit www.numirabio.com.

About vSpring Capital

vSpring Capital (www.vspring.com) is a traditional early-stage venture capital firm with over \$390 million of committed capital under management. The firm targets information technology and life sciences companies with the potential to transform their markets and create lasting value. Their primary areas of focus include enterprise software, networking and communications, security software, Internet, mobile computing, drug discovery, drug delivery, diagnostics, and medical devices, all markets where the firm has deep experience.

About Crocker Ventures

Crocker Ventures is a privately-held early-stage biotech/life science investment firm created by prominent serial life science entrepreneur Gary Crocker. Crocker's multifaceted career includes experience as current chairman of Merrimack Pharmaceuticals; founder and CEO of Research Medical, a leading publicly-traded cardiac surgery company sold to Baxter International in 1997; co-founder of TheraTech, a leader in trans-dermal drug delivery technologies sold to Watson Pharmaceuticals in 1999; chairman of ARUP Laboratories, one of the nation's largest diagnostic reference laboratories; and a seven-year board member of the Federal Reserve Branch of San Francisco. Crocker has been inducted into the University of Utah Science Hall of Fame, serves as a director of the University's Research Foundation and has been selected as Utah Entrepreneur of the Year by both Ernst & Young and the MountainWest Capital Network.